- Home
- BZAI vs CRMD Comparison
BZAI vs CRMD Comparison
Compare BZAI & CRMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BZAI
- CRMD
- Stock Information
- Founded
- BZAI 2010
- CRMD 2006
- Country
- BZAI United States
- CRMD United States
- Employees
- BZAI N/A
- CRMD N/A
- Industry
- BZAI
- CRMD Biotechnology: Pharmaceutical Preparations
- Sector
- BZAI
- CRMD Health Care
- Exchange
- BZAI Nasdaq
- CRMD Nasdaq
- Market Cap
- BZAI 684.9M
- CRMD 645.0M
- IPO Year
- BZAI N/A
- CRMD 2010
- Fundamental
- Price
- BZAI $2.77
- CRMD $7.67
- Analyst Decision
- BZAI Strong Buy
- CRMD Strong Buy
- Analyst Count
- BZAI 1
- CRMD 6
- Target Price
- BZAI $10.00
- CRMD $14.50
- AVG Volume (30 Days)
- BZAI 657.2K
- CRMD 2.6M
- Earning Date
- BZAI 05-15-2025
- CRMD 05-08-2025
- Dividend Yield
- BZAI N/A
- CRMD N/A
- EPS Growth
- BZAI N/A
- CRMD N/A
- EPS
- BZAI N/A
- CRMD N/A
- Revenue
- BZAI $1,554,000.00
- CRMD $43,472,170.00
- Revenue This Year
- BZAI N/A
- CRMD $207.65
- Revenue Next Year
- BZAI N/A
- CRMD $50.13
- P/E Ratio
- BZAI N/A
- CRMD N/A
- Revenue Growth
- BZAI N/A
- CRMD N/A
- 52 Week Low
- BZAI $1.70
- CRMD $3.61
- 52 Week High
- BZAI $29.61
- CRMD $13.85
- Technical
- Relative Strength Index (RSI)
- BZAI N/A
- CRMD 47.85
- Support Level
- BZAI N/A
- CRMD $6.32
- Resistance Level
- BZAI N/A
- CRMD $7.71
- Average True Range (ATR)
- BZAI 0.00
- CRMD 0.47
- MACD
- BZAI 0.00
- CRMD 0.23
- Stochastic Oscillator
- BZAI 0.00
- CRMD 92.41
About BZAI Blaize Holdings Inc. Common Stock
Blaize Holdings Inc provides customized,programmable processor architecture suite, artificial intelligence (AI)-enabled edge computing solutions. The company offers semiconductor and software technology company dedicated to revolutionizing the world of AI.
About CRMD CorMedix Inc.
Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets.